The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study

American Journal of Preventive Cardiology

Marcio Sommer Bittencourt¹  Miguel Cainzos-Achirica²  Mouaz Al-Mallah³  Catherine Teng⁴  Raul D. Santos⁵  Chukwuemeka U. Osondu⁶  Khurram Nasir⁷  Matthew Buddoff⁸  Ahmed Soliman⁸  Edison R. Parise⁸  Ehimen C. Aneni⁹ 

[1] Corresponding author.;Hospital Israelita Albert Einstein, São Paulo, Brazil;Baptist Health South Florida, Miami, FL, USA;Center for Clinical and Epidemiological Research, University Hospital and State of São Paulo Cancer Institute (ICESP), University of São Paulo, São Paulo, Brazil;David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA;Department of Internal Medicine, Yale New Haven Health - Greenwich Hospital, Greenwich, CT, USA;Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil;Houston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USA;Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA;

关键词: Non-alcoholic fatty liver disease;    Cardiometabolic disease;    Lean individuals;    Inflammation;    Triglycerides;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) in lean (BMI<25 ​kg/m2) individuals presents a distinct phenotype. We sought to determine the cardiometabolic consequences of lean NAFLD in a population cohort of relatively young asymptomatic individuals who participated in a voluntary routine health promotion evaluation in Brazil. Methods: We analyzed data in our population collected from 2004 to 2016. Medical and demographic history, anthropometric measures, and fasting blood samples were obtained. Participants had ultrasonography to assess for fatty liver. We defined NAFLD as fatty liver in individuals scoring below 8 on the alcohol use disorders identification test (AUDIT). We included data from 9137 individuals who had complete data at baseline and at follow-up. Results: The prevalence of lean NAFLD in our cohort was 3.8%. Over the median follow-up period of 2.4 years (range 0.5–9.9 years), lean individuals had 74% (HR: 1.74 (1.39–2.18)) and 67% (1.67 (1.29–2.15)) greater risk of developing elevated BP and elevated glucose, and nearly 3 times the risk of atherogenic dyslipidemia (HR: 2.98 (2.10–4.24)) compared to lean individuals without NAFLD. Lean NAFLD individuals also had higher risk of developing elevated glucose (HR: 1.37 (1.07–1.75)) and atherogenic dyslipidemia (1.46 (1.05–2.01)) compared to non-lean individuals without NAFLD. However, there was no significant difference in the risk of elevated BP, elevated glucose or atherogenic dyslipidemia between lean NAFLD and non-lean individuals with NAFLD in fully adjusted models. Conclusion: Lean NAFLD is not metabolically benign. Further cardiovascular risk stratification and appropriate preventive measures should be considered in lean individuals who present with NAFLD.

【 授权许可】

Unknown